Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3–6/6 HLA matched donors-Reference-Cited by-同舟云学术

Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3–6/6 HLA matched donors

Published:2008-10-13 Issue:4 Volume:43 Page:327-333
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Rizzieri D A,Dev P,Long G D,Gasparetto C,Sullivan K M,Horwitz Ml,Chute J,Chao N J

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/bmt2008321.pdf

Reference36 articles.

1. de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C et al. Nonablative versus reduced intensity conditioning regimens in the treatment of AML and high risk MDS: dose is relevant to long term disease control. Blood 2004; 104: 865–872.

2. Martino R, Iacobelli S, Brand R, Jansen T, van Biezen A, Finke J et al. Myelodysplastic Syndrome subcommittee of the Chronic Leukemia Working Party of the European Blood and Marrow Transplantation Group. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 2006; 108: 836–846.

3. Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S et al. In vivo CAMPATH—1H prevents graft versus host disease following nonmyeloablative stem cell transplantation. Blood 2000; 96: 2419–2425.

4. Rizzieri DA, Koh LP, Long GD, Gasparetto C, Vredenburgh J, Smith C et al. Clinical outcome and immune reconstitution following Alemtuzumab T cell depleted mismatched non-myeloablative allogeneic immunotherapy. J Clin Oncol 2007; 25: 690–697.

5. Giralt S, Estey E, Albitar M, van Besien K, Rondón G, Anderlini P et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analogue-containing chemotherapy: harness engraft vs leukemia without myeloablative therapy. Blood 1997; 89: 4531–4536.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Retrospective, Landmark Analysis of Long-term Adult Morbidity Following Allogeneic HSCT for Inborn Errors of Immunity in Infancy and Childhood;Journal of Clinical Immunology;2022-05-17

2. Phase I dose escalation study of naive T-cell depleted donor lymphocyte infusion following allogeneic stem cell transplantation;Bone Marrow Transplantation;2020-07-05

3. Preclinical safety evaluation of chimeric antigen receptor-modified T cells against CD19 in NSG mice;Annals of Translational Medicine;2019-12

4. NK Cell and NKT Cell Immunotherapy;Immunotherapy for Pediatric Malignancies;2017-11-22

5. Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT;Bone Marrow Transplantation;2013-05-20